0.7499

2.61% -0.0201

Alzamend Neuro Inc (ALZN)

Überblick Nachrichten Preisverlauf Financials Warum fällt ALZN? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$0.77

Offen:

$0.8

24-Stunden-Volumen:

38,478

Relative Volume:

0.11

Marktkapitalisierung:

$5.08M

Einnahmen:

Nettoeinkommen (Verlust:

$-5.85M

KGV:

-0.1121

EPS:

-6.6877

Netto-Cashflow:

$-8.00M

1W Leistung:

-23.69%

1M Leistung:

+7.44%

6M Leistung:

-54.83%

1J Leistung:

-91.60%

1-Tages-Spanne:

$0.73

$0.8119

1-Wochen-Bereich:

$0.7206

$0.9789

52-Wochen-Spanne:

$0.6427

$15.06

Alzamend Neuro Inc Stock (ALZN) Company Profile

Firmenname

Alzamend Neuro Inc

Sektor

Healthcare (1159)

Branche

Biotechnology (667)

Telefon

844-722-6333

Adresse

3500 LENOX RD. NE, ATLANTA

Mitarbeiter

Twitter

Nächster Verdiensttermin

2024-09-12

Neueste SEC-Einreichungen

ALZN's Discussions on Twitter

Vergleichen Sie ALZN mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ALZN Alzamend Neuro Inc	0.7499	5.08M	0	-5.85M	-8.00M	-6.6877
VRTX Vertex Pharmaceuticals Inc	481.03	122.24B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	547.77	59.73B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	579.54	35.29B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	233.66	29.62B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	226.95	22.44B	3.81B	-644.79M	-669.77M	-6.24

Alzamend Neuro Inc Stock (ALZN) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2021-10-01	Eingeleitet	Ascendiant Capital Markets	Buy

Alzamend Neuro Inc Aktie (ALZN) Neueste Nachrichten

Apr 08, 2025

Alzamend Neuro (ALZN) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? - Yahoo Finance

Apr 08, 2025

Mar 30, 2025

Alzamend Neuro, Inc. (NASDAQ:ALZN) Short Interest Update - Defense World

Mar 30, 2025

Mar 28, 2025

Is Alzamend Neuro, Inc. (ALZN) the Cheapest Stock Insiders Are Buying In March? - Insider Monkey

Mar 28, 2025

Mar 27, 2025

Alzamend neuro director William Horne buys $3,285 in common stock By Investing.com - Investing.com Australia

Mar 27, 2025

Alzamend neuro director William Horne buys $3,285 in common stock - Investing.com India

Mar 27, 2025

Mar 26, 2025

Alzamend Neuro director Milton Ault buys $2,968 in company stock - Investing.com India

Mar 26, 2025

Mar 25, 2025

Alzamend Neuro director Milton Ault buys $2,968 in company stock By Investing.com - Investing.com South Africa

Mar 25, 2025

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer's Disease to take Place at Massachusetts General Hospital - The Manila Times

Mar 25, 2025

Major Breakthrough: New Alzheimer's Drug Advances to Phase II at Top Hospital - Stock Titan

Mar 25, 2025

Mar 24, 2025

Alzamend Neuro CFO David Katzoff acquires $5,048 in common stock By Investing.com - Investing.com Australia

Mar 24, 2025

Alzamend Neuro CFO David Katzoff acquires $5,048 in common stock - Investing.com

Mar 24, 2025

Mar 20, 2025

Alzamend Neuro director William B. Horne purchases $4,891 in shares - Investing.com India

Mar 20, 2025

Alzamend Neuro director William B. Horne purchases $4,891 in shares By Investing.com - Investing.com UK

Mar 20, 2025

Alzamend Neuro director William B. Horne buys $4,851 in stock - Investing.com India

Mar 20, 2025

Mar 19, 2025

Alzamend Neuro director William B. Horne buys $4,851 in stock By Investing.com - Investing.com South Africa

Mar 19, 2025

Alzamend Neuro director Milton C. Ault III acquires $4,810 in shares - Investing.com Australia

Mar 19, 2025

Mar 18, 2025

Alzamend Neuro director Milton C. Ault III acquires $4,810 in shares By Investing.com - Investing.com South Africa

Mar 18, 2025

Alzamend Neuro, Inc. Plans Phase II Clinical Study of AL001 in Major Depressive Disorder to Compare Lithium Delivery with Marketed Products - Nasdaq

Mar 18, 2025

Alzamend Neuro Announces Initiation Date of Phase II - GlobeNewswire

Mar 18, 2025

Major Depression Breakthrough: New Lithium Treatment Heads to Phase II at Top Hospital - StockTitan

Mar 18, 2025

Mar 17, 2025

Alzamend Neuro (ALZN) Projected to Post Earnings on Monday - Defense World

Mar 17, 2025

Mar 15, 2025

Alzamend Neuro director Milton Ault buys $68 in stock By Investing.com - Investing.com Australia

Mar 15, 2025

Mar 14, 2025

Alzamend Neuro director Milton Ault buys $68 in stock - Investing.com

Mar 14, 2025

Mar 13, 2025

Short Interest in Alzamend Neuro, Inc. (NASDAQ:ALZN) Rises By 332.2% - Defense World

Mar 13, 2025

Mar 11, 2025

Alzamend Neuro stock hits 52-week low at $0.68 amid sharp decline - Investing.com Australia

Mar 11, 2025

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Post-Traumatic Stress Disorder to take Place at Massachusetts General Hospital - BioSpace

Mar 11, 2025

Alzamend Neuro stock hits 52-week low at $0.68 amid sharp decline By Investing.com - Investing.com South Africa

Mar 11, 2025

Alzamend Neuro plans mid-stage study of its therapy for PTSD in fourth-quarter 2025 - Marketscreener.com

Mar 11, 2025

Major PTSD Breakthrough: New Lithium Treatment Heads to Phase II Trial at Top Hospital - StockTitan

Mar 11, 2025

EXCLUSIVE: Alzamend Neuro To Launch Phase 2 Study For Lead Drug For PTSD Patients In Late 2025 To Assess Lithium Delivery Benefits - Benzinga

Mar 11, 2025

Mar 10, 2025